[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-cancer-ovca\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-cancer-ovca":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,73,101,126,157,181,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637456","rectosigmoid-lesion-excision-vs-resection-a-non-inferiority-randomized-comparison-in-advanced-ovarian-cancer-100637456",false,"NCT07616310","Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer","A Prospective Randomized Controlled Non-Inferiority Study Comparing the Efficacy of Lesion Excision Versus Rectosigmoid Resection in Pelvic Cytoreductive Surgery for Advanced Ovarian Cancer","RSEnTrail","Inclusion Criteria:\n\n* Voluntarily participate in this study and sign the informed consent form;\n* Age 18-70 years old;\n* Primary debulking surgery for epithelial ovarian cancer (including neoadjuvant chemotherapy), with or without abdominal and distant metastasis (≥ IIB stage);\n* Colonoscopy negative (no mucosal layer invasion);\n* Preoperative imaging (enhanced pelvic MRI) assesses the tumor's involvement of the intestinal surface and\u002For major parts of the mesentery;\n* Eastern Cooperative Oncology Group (ECOG) score \\\u003C 3;\n* American Society of Anesthesiologists (ASA) score \\\u003C 3.\n\nExclusion Criteria:\n\n* Has a history of other malignant tumors or is undergoing other anti-tumor treatments;\n* Has severe underlying medical conditions that make surgery intolerable;\n* Epithelial ovarian cancer diagnosed incidentally during emergency surgery;\n* Participates in other clinical studies simultaneously;\n* Secondary cytoreductive surgery for epithelial ovarian cancer;\n* Patients who have received radiotherapy to the abdomen or pelvis before.","FEMALE","18 Years","70 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.",[28],"Ovarian Cancer (OvCa)",[30,31],"Rectosigmoid Resection","Rectosigmoid Lesion Excision","RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2024-01-10",{"date":40,"type":22},"2028-12-31",{"name":42,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100639053","a-prospective-observational-study-of-senaparib-in-the-treatment-of-epithelial-ovarian-cancer-100639053","NCT07586449","A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer","Evaluation of Safety and Effectiveness of Senaparib in Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer: A Prospective Observational Real-World Study","RESO","Inclusion Criteria:\n\n* Sign informed consent and voluntarily join the study;\n* Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology;\n\n  -≥ 18 years old;\n* The investigator determined that the patient could receive senaparib monotherapy or combination therapy;\n* For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of senaparib\n\nExclusion Criteria:\n\n* There is evidence that the patient is a pregnant or lactating woman;\n* Participating in any research with intervention measures other than routine -clinical practice;\n* The researcher judges other situations that are not suitable for inclusion in the study;",{"count":54,"type":22},500,"6 Years","OBSERVATIONAL","Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis.\n\nThis observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。",[28],[60,61,62],"senaparib","real word study","ovarian cancer","NOT_YET_RECRUITING","2026-05-08",{"date":66,"type":36},"2026-05-14",{"date":68,"type":22},"2026-06-10",{"date":70,"type":22},"2030-12-31",{"name":72,"class":43},"Zhejiang Cancer Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":44},"100619095","phase-2-trastzumab-deruxtecan-versus-soc-in-recurrent-ovarian-that-progressed-on-prior-parp-inhibitor-therapy-100619095","NCT07340164","Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","A Phase 2, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan Versus Investigator's Choice Chemotherapy in Recurrent Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy: TROY (APGOT-OV14)","TROY","Inclusion Criteria:\n\n* 1\\. Adults ≥18 years of age on the day of signing the Informed Consent Form. Follow local regulatory requirements if the legal age of consent for trial participation is \\>18 years old.\n\n  2\\. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.\n\n  3\\. Has HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+\u002F2+\u002F1+) guidelines by local tests.\n\n  4\\. Availability of tumor tissue for translational research: A formalin-fixed paraffin-embedded (FFPE) tumorblock (preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.\n\n  5\\. Histologically confirmed high grade serous or high grade endometrioid ovarian, primary peritoneal, and\u002For fallopian tube cancer that is recurrent.\n\n  6\\. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Radiologically confirmed\u002Fdocumented disease progression while on PARP inhibitor therapy in either first or second-line maintenance setting Note: Documentation of disease progression must be within 180 days of last PARPi dose taken. Surgical salvage intervention and\u002For focal ablative therapies are allowed.\n  1. Clinically benefited from PARPi maintenance prior to documented progression, as defined by at least 6 months of treatment duration with no progressive disease observed.\n  2. Progression on first-line maintenance PARP inhibitor: Participants are allowed maximum 1 additional line of platinum-based chemotherapy before study entry (note: treatment-free interval on platinum rechallenge must be \\> 6 months, with documented disease progression prior to study entry.\n  3. Progression on second-line maintenance PARP inhibitor: Participants are not allowed any additional systemic anticancer treatment before study entry.\n\n     8\\. Patient with measurable disease according RECIST 1.1 criteria. 9. LVEF ≥50% within 28 days before randomization. 10. Patient has adequate organ function, defined as follows:\n\n  a) Absolute neutrophil count ≥ 1,500 cells\u002FμL b) Platelets ≥ 100,000 cells\u002FμL c) Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL d) Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50mL\u002Fmin using the Cockcroft-Gault equation for patients with creatinine levels \\> 1.5× institutional ULN e) Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN g) International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN. Patients receiving anticoagulant therapy must have a PT or partial thromboplastin within the therapeutic range of intended use of anticoagulants.\n\n  11\\. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of nonchildbearing potential. Nonchildbearing potential is defined as follows:\n  1. Patient is ≥ 45 years of age and has not had menses for \\> 1 year.\n  2. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \\\u003C 2 years without a hysterectomy and oophorectomy.\n  3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:\n* Documented hysterectomy or bilateral oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.\n* Tubal ligation must be confirmed with medical records of the actual procedure.\n* Information must be captured appropriately within the site's source documents. 12. Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 150 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents) 13. Has proteinuria \\\u003C2+. If proteinuria is ≥2+, 24-hour urine must demonstrate \\\u003C1 g of protein in 24 hours.\n\nExclusion Criteria:\n\n\\- 1. Primary platinum-refractory disease defined as disease progression during primary platinum-based chemotherapy or platinum-resistant disease defined as disease progression within 6 months of the last platinum administration in the second-line setting.\n\n2\\. History of additional malignancy within 3 years before the date of enrolment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor, is considered cured with minimal risk of recurrence within 3 years. 3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \\\u003C 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.\n\nNote: The washout period for radiation therapy is as follows: ≥ 4 weeks for palliative stereotactic radiation to chest and ≥2 weeks palliative stereotactic radiation therapy to other anatomic areas.\n\n4\\. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n\nNote: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability. 5. Active and\u002For uncontrolled infection. The following exceptions apply:\n\n1. Participants with HIV infection are eligible if followings are met: a. CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening, b. Virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) at the time of screening and for at least 12 weeks before screening, c. No AIDS-defining opportunistic infections or conditions within the past 12 months, d. On stable ART regimen, without changes in drugs or dose modification, for at least 4 weeks before trial entry (Day 1) and agree to continue ART throughout the trial.\n2. Participants with evidence of chronic HBV infection are eligible if the followings are met: a. the HBV viral load is \\\u003C2000 IU\u002FmL b. start or maintain antiviral treatment, if clinically indicated as per the investigator. c. they have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HBV infection.\n3. Participants with a history of HCV infection are eligible if History of hepatitis C infection eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks and if they Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HCV infection.\n\n   6\\. Patient has not recovered (i.e., to Grade ≤ 1 or to baseline) from cytotoxic therapy-induced adverse events(AEs).\n\nNote: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.\n\n7\\. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.\n\n8\\. Patient has a known hypersensitivity to the active substances or to any excipients of the study intervention 9. Evidence of active or ongoing bowel obstruction 10. Has a history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required corticosteroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n11\\. Uncontrolled or significant cardiovascular disease, including the following:\n\n1. QT interval corrected with Fridericia's formula interval \\>470 ms (average of triplicate determinations).\n2. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.\n3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.\n4. Myocardial infarction within 6 months prior to screening.\n5. Uncontrolled angina pectoris within 6 months prior to screening.\n6. New York Heart Association Class 2 to 4 congestive heart failure.\n7. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.\n8. Complete left or right bundle branch block.\n9. Patients with troponin levels above ULN at screening (as defined by the manufaccturer), and wit any MI related symptoms. (For patients with elevated troponin levels but no MI symptoms, a cardiology consultation during the screening period is recommended..\n\n   12\\. Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.\n\n   13\\. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) 14. Patients with current abdominal\u002F pelvic fistula. 15. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study(including obtaining informed consent).\n\n   16\\. Prior exposure to other HER2-targeted agents or antibody-drug conjugate that consists of an exatecan derivative that is a topoisomerase I inhibitor 17. Patient is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 7 months after the last dose of study treatment, or lactating woman.\n\n   18\\. Live vaccines within 30 days of first dose of study intervention and while receiving study intervention. Administration of inactivated vaccines (i.e. inactivated influenza vaccine) is permitted. Inactivated RNA or nonreplicating viral vector-based SARS-CoV-2 vaccines are allowed, as approved by local\u002Fregional Health Authorities. Novel live attenuated SARS-CoV-2 vaccines are not permitted.",{"count":82,"type":22},116,[84],"PHASE2","Ovarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free survival (PFS). However, most patients eventually develop resistance to PARP inhibitors and become unresponsive to conventional treatments. Therefore, an effective standard treatment for patients who relapse after PARP inhibitor resistance has not yet been established. Meanwhile, HER2 protein expression has been identified in some patients, drawing attention as a new therapeutic target.\n\nTrastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting HER2, has already demonstrated efficacy and safety in other HER2-positive cancers. This study aimed to explore the potential of T-DXd as a new treatment option by evaluating the efficacy and safety of T-DXd in patients with ovarian, fallopian tube, and peritoneal cancer who relapsed after PARP inhibitor treatment and who express HER2.\n\nParticipants will:\n\n* Arm A: T-DXd +\u002F- Bevacizumab, IV, every 3weeks\n* Arm B: Platinum-based chemotherapy +\u002F- Bevacizumab, IV",[87,88,89,28],"Ovarian Cancer","Ovarian Carcinoma, Recurrent","Ovarian Cancer Metastatic Recurrent",[79,91,92],"APGOT-OV14","ENGOT-ov92","2026-04-17",{"date":95,"type":36},"2026-04-20",{"date":97,"type":36},"2026-02-26",{"date":70,"type":22},{"name":100,"class":43},"Yonsei University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100596845","phase-2-comprehensive-multimodal-prehabilitation-alone-or-with-neoadjuvant-therapy-before-major-cancer-surgery-100596845","NCT07050771","Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery","Comprehensive Multimodal Prehabilitation Alone or in Combination With Planned Neoadjuvant Therapy in High-risk Patients Prior to Elective Major Cancer Surgery","Inclusion Criteria:\n\nPatients are eligible for entry into the study (First Registration) only if ALL of the following criteria apply. No exceptions or waivers will be granted for patients who do not meet the eligibility criteria.\n\n* Signed informed consent form.\n* Age ≥18 years at time of signing informed consent form.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 per the treating cancer surgeon (Arm 1, Neoadjuvant therapy) or per both the treating cancer surgeon and the medical and\u002For radiation oncologists (Arm 2, no neoadjuvant therapy).\n* Pre-frail or frail (based on the Fried Frailty Phenotype\n* Probable or proven (histologically confirmed) pancreaticobiliary\u002Fperiampullary (i.e., pancreatic cancer, cholangiocarcinoma, duodenal cancer, or ampullary cancer), ovarian cancer, kidney cancer, or bladder cancer based on central pathological review at Houston Methodist Hospital.\n* Clinically non-metastatic (stage I-III) or metastatic (IV) disease.\n* Technically resectable disease (no significant vascular, neural, or bony involvement and potential to safely achieve R0 resection) and potentially medically fit for EMCS per the treating cancer surgeon (surgical oncologist\u002FHBP surgeon, gynecologic oncologist, or urologic oncologist).\n* Tentatively scheduled to undergo elective pancreatectomy (open or minimally invasive pancreaticoduodenectomy or open distal pancreatectomy) for pancreaticobiliary\u002Fperiampullary cancer, elective surgical cytoreduction for ovarian cancer, elective open radical nephrectomy for kidney cancer, or elective (open or minimally invasive) total cystectomy for bladder cancer by one of the study MPI or Co-Is \\> 28 days after trial registration.\n* Neoadjuvant therapy group only: Completed planned NAT (if any) at least 2 weeks prior to Study Registration.\n* No neoadjuvant therapy group only: Medically fit and planned to receive NAT per the treating medical and\u002For radiation oncologist.\n* Ability to comply with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.\n* Willing and able to consume a lactose-free, whey protein supplement (if not allergic to milk protein\u002Fsoy and no history of galactosemia), marine protein supplement (if not allergic to marine protein\u002Fshellfish), or pea protein supplement (if not allergic to pea protein).\n* Willing to provide tissue and blood specimens as per protocol.\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen.\n* Access to a smart phone (personally or via caretaker who resides with the patient).\n* Understands, speaks, and reads English.\n\nExclusion Criteria:\n\nPatients are NOT eligible for entry into the study (First Registration) only ANY of the following criteria apply. No exceptions or waivers will be granted for patients who do not meet the eligibility criteria.\n\n* Difficulty or inability to hear and\u002For understand loud speech and sounds.\n* Unable to eat by mouth (e.g., tube feed dependent, on total parenteral nutrition, etc.)\n* Oxygen dependent (or rest and\u002For with exertion).\n* Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification III or IV, unstable angina, unstable arrhythmia, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of trial treatment.\n* Dependence on mobility device for ambulation other than a cane (e.g., crutches, walker, wheelchair).\n* Active brain metastasis or leptomeningeal disease.\n* Active bone metastasis and\u002For recent bone fracture.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). NOTE: Patients with indwelling catheters (e.g., PleurX) are allowed\n* Planned receipt of investigational therapy\u002Ftreatment (other than the protocol-mandated CMMP intervention) during the trial treatment.\n* Major procedure\u002Fsurgery within 12 weeks prior to initiation of trial treatment that would prevent the patient from complying with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.\n* Active physical\u002Fmental condition or personal\u002Fsocial circumstance that would prevent the patient from complying with the CMMP intervention and study assessments as per protocol, in the MPI's judgment.","ALL",{"count":110,"type":22},148,[84],"In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail\u002Ffrail patients with probable\u002Fproven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).",[114,28,115,116],"Hepatopancreaticobiliary (HPB) Malignancy","Kidney Cancers","Bladder Cancer","2026-03-10",{"date":119,"type":36},"2026-03-12",{"date":121,"type":36},"2025-08-14",{"date":123,"type":22},"2027-10-01",{"name":125,"class":43},"The Methodist Hospital Research Institute",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":44},"100614943","phase-3-trauma-focused-managing-cancer-and-living-meaningfully-calm-tf-for-newly-diagnosed-and-recurrent-ovarian-cancer-100614943","NCT07286162","Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer","Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF): A Phase III Randomized Controlled Trial of an Intervention Targeting Traumatic Stress in Patients With Advanced Ovarian Cancer","CALM-TF","Inclusion Criteria:\n\n* Newly diagnosed stage III or IV ovarian cancer OR recurrent ovarian cancer within six months of diagnosis or recurrence\n* Age 18 years or older\n* Able to speak and read English\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Significant cognitive impairment that would interfere with the ability to participate in psychotherapy or complete study questionnaires\n* Active psychosis or severe psychiatric condition requiring immediate psychiatric intervention\n* Receiving ongoing psychotherapy at the time of recruitment",{"count":21,"type":22},[136],"PHASE3","The goal of this clinical trial is to investigate if CALM-TF (Trauma-Focused Managing Cancer and Living Meaningfully) is effective in treating traumatic stress symptoms in women with advanced ovarian cancer. It will also learn whether the efficacy differs at new diagnosis versus at recurrence.\n\nThe main questions it aims to answer are:\n\n1. What is the effectiveness of CALM-TF in reducing traumatic stress symptoms in patients with newly diagnosed or recurrent advanced ovarian cancer, as measured at 3 and 6 months?\n2. What are the effects of CALM-TF on depression, quality of life, and patient-perceived benefit of the intervention compared to usual care alone?\n3. What are patient perceptions of their care experiences as explored through qualitative interviews?\n\nResearchers will compare CALM-TF to usual standard of care (which includes regular conversations with medical teams and meetings with social workers) to see if CALM-TF works to treat traumatic stress.\n\nParticipants will:\n\n* Receive 3-6 sessions of CALM-TF over 3-6 months (45-60 minutes each) via video call, telephone, or in-person based on preference, OR receive usual care only\n* Complete questionnaires at baseline, 3 months, and 6 months\n* Continue to receive their standard cancer care throughout the study\n* Some participants may be invited to participate in qualitative interviews at 6 months",[28,139],"Recurrent Ovarian Cancer",[141,62,142,143,144,145,146,147],"randomized controlled trial","recurrence","newly diagnosed","CALM","Managing Cancer And Living Meaningfully","Psychotherapy","psychosocial support","2026-01-23",{"date":150,"type":36},"2026-01-27",{"date":152,"type":22},"2026-03-01",{"date":154,"type":22},"2031-12-31",{"name":156,"class":43},"University Health Network, Toronto",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100602005","phase-2-etoposide-capsules-combined-with-bevacizumab-and-iparomlimab-and-tuvonralimab-in-the-treatment-of-platinum-resistant-or-platinum-refractory-ovarian-cancer-100602005","NCT07117877","Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer","Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer: a Single Arm, Open, Single Center, Phase II Clinical Study","Inclusion Criteria:\n\n1. Age: 18-75, female;\n2. According to RECIST 1.1 criteria, there are measurable lesions at baseline;\n3. ECOG PS： 0-1；\n4. Epithelial ovarian, fallopian tube, and primary peritoneal cancer with platinum resistance or platinum refractory recurrence; Provide 10 white films for pathological type confirmation and efficacy marker exploration, and meet all of the following conditions.\n\n   ① Received systemic treatment with ≥ 1 line and ≤ 6 lines, among which only received systemic treatment with ≤ 4 lines after platinum resistance relapse.\n\n   ② Previous treatments should include at least one platinum based chemotherapy regimen. There are two specific situations:\n   1. For patients who have only received 1-line platinum based chemotherapy in the past, disease remission (CR or PR) must be achieved, and disease progression must occur within a period of ≥ 4 weeks and\\\u003C6 months after the last platinum based chemotherapy.\n   2. For patients who have received systemic treatment from line 2 to line 5 in the past, it is required that disease progression must occur within a period of less than 6 months after the last platinum based chemotherapy.\n\n   Note: When determining the number of lines, the following requirements should be noted:\n\n   The overall count of neoadjuvant ± adjuvant systemic therapy is one line. Maintenance treatment does not calculate the number of lines separately. Simple endocrine therapy is counted as a baseline, but the use of endocrine therapy due to non disease progression (such as only elevated CA-125) is not counted as a baseline.\n\n   Changing the treatment plan due to intolerance without disease progression is not considered as changing the line.\n\n   The subject needs to experience disease progression after the final systemic treatment.\n5. The main organ functions well and meets the following criteria:\n\n   1. Blood routine examination (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days): hemoglobin (Hb) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; platelet count (PLT) ≥ 90 × 109\u002FL;\n   2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for tumor liver metastases); Serum total bilirubin (TBIL) ≤ 1.5 × ULN (Gilbert syndrome subjects, ≤ 3 × ULN); Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate ≥ 60mL\u002Fmin;\n   3. Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN;\n   4. Urine routine examination shows urinary protein\\\u003C2+; If urinary protein is ≥ 2+, 24-hour urinary protein quantification should be\\\u003C1 g;\n   5. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ 50%.\n6. Non surgical sterilization or female patients of childbearing age are required to use two medically approved contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo non-surgical sterilization must have a negative serum HCG test within 72 hours before their first medication and must be non lactating; For male patients whose partners are women of childbearing age, two effective methods of contraception should be used during the study treatment period and within 3 months after the end of the study treatment period.\n7. The subjects voluntarily joined this study, signed informed consent forms, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n1. Patients who participate in other clinical trials simultaneously;\n2. Allergic constitution, including a history of severe drug allergies or drug allergic reactions; Known to be allergic or intolerant to the investigational drug;\n3. No measurable lesions or lesions that cannot be evaluated;\n4. Patients with untreated central nervous system metastases, who have previously received systemic or curative treatment for brain or meningeal metastases (radiotherapy or surgery), have been confirmed stable for at least one month by imaging, and have stopped systemic hormone therapy (dose\\>10mg\u002Fday prednisone or other therapeutic hormones) for more than two weeks without clinical symptoms can be included;\n5. Those who are unable to swallow pills normally or have gastrointestinal dysfunction, as determined by researchers, may affect drug absorption;\n6. Individuals who have experienced intestinal obstruction within the past 3 months;\n7. At present, there are uncontrollable malignant pleural effusion, ascites, or pericardial effusion (defined as those that cannot be effectively controlled by diuretics or puncture methods as determined by researchers);\n8. Suffering from uncontrolled comorbidities, including but not limited to: active HBV or HCV infection; Known history of HIV infection or AIDS; Active syphilis; Active tuberculosis; Active infection; Uncontrolled hypertension and symptomatic heart failure; Active bleeding;\n9. History of myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or other malignant tumors within 5 years prior to the initial administration of the study (excluding completely relieved carcinoma in situ and malignant tumors with slow progression determined by the investigator)\n10. Other incurable malignant tumors in the past (within 5 years) or at the same time, except for cured skin basal cell carcinoma, cervical carcinoma in situ and breast cancer with no recurrence after radical surgery\\>3 years;\n11. Pregnant or lactating women;\n12. According to the researchers' assessment, there may be other factors that could lead to the forced termination of this study, such as other serious illnesses (including mental illnesses) requiring concurrent treatment, serious laboratory abnormalities, and family or social factors that could affect the safety of the subjects or the collection of data and samples.","75 Years",{"count":166,"type":22},33,[84],"This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people with platinum-resistant or platinum refractory ovarian cancer . Researchers will look at the Progression-Free Survival, Objective Response Rate, Overall Survival, safety, and any side effects.",[170,171,28],"Platinum Resistant Ovarian Cancer","Platinum Refractory Epithelial Ovarian Cancer","2025-08-22",{"date":174,"type":36},"2025-08-28",{"date":176,"type":22},"2025-09-15",{"date":178,"type":22},"2027-08-31",{"name":180,"class":43},"Fudan University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":190,"studyType":56,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100600653","anatomopathological-analysis-of-the-infundibulopelvic-ligament-in-patients-with-ovarian-cancer-100600653","NCT07100288","Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer","INFPELV","Inclusion Criteria:\n\n* ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma.\n\n  * FIGO 2014 stage IA-IVB.\n  * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy\n  * Patients with no residual disease after surgery.\n  * Patients with ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* ◦ Patients without epithelial ovarian cancer.\n\n  * Patients with ECOG 2-4.\n  * Patients who do not consent to participate in the study.\n  * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.",{"count":189,"type":22},200,"2 Years","Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis",[87,28,193],"Ovarian Adenocarcinoma","2025-07-27",{"date":196,"type":36},"2025-08-03",{"date":198,"type":36},"2025-07-20",{"date":200,"type":22},"2030-12-30",{"name":202,"class":43},"Complejo Hospitalario Universitario Insular Materno Infantil",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":211,"studyType":56,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":44},"100574564","urinary-proteomic-assessment-of-ovarian-malignancy-and-disease-progression-100574564","NCT06760923","Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression","Inclusion Criteria:\n\n* Female patients in the gynecological ward for surgical treatment.\n* Initial diagnosis of \"pelvic mass\" or \"malignant ascites\" may be considered as ovarian cancer; Or the initial diagnosis of \"ovarian cyst\", \"hydrosalpinx\", \"uterine fibroids\" or \"uterine adenomyosis\" are considered as gynecological non-malignant diseases.\n* Over 18 years of age.\n* Voluntary participation and signing of informed consent.\n\nExclusion Criteria:\n\n* Study participants with a prior history of malignant tumors.\n* Study participants with prior chronic kidney disease or renal insufficiency.\n* Study participants who have received or are receiving treatment for primary disease.\n* Study participants whose pathological diagnosis was not clear.\n\nAny patient should be excluded from the study if:\n\n* Study participants withdraw informed consent and request withdrawal.\n* Study participants were unable to provide a qualified urine sample.\n* There are situations in which the researcher considers it necessary to withdraw from the study.",{"count":210,"type":22},240,"6 Months","The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are:\n\n1. What is the difference in urinary protein composition between patients with ovarian cancer and those without it?\n2. Can these differences in urinary protein composition aid in the diagnosis of ovarian cancer?\n3. Are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer?\n4. Can urinary protein markers be used for disease surveillance in ovarian cancer patients?",[28],"2025-01-06",{"date":216,"type":36},"2025-01-07",{"date":218,"type":22},"2025-01-01",{"date":220,"type":22},"2027-12-31",{"name":222,"class":43},"Xiangya Hospital of Central South University"]